Literature DB >> 30070776

Muscular Dystrophy Surveillance, Tracking, and Research Network pilot: Population-based surveillance of major muscular dystrophies at four U.S. sites, 2007-2011.

ThuyQuynh N Do1, Natalie Street1, Jennifer Donnelly2, Melissa M Adams3, Christopher Cunniff4, Deborah J Fox5, Richard O Weinert2, Joyce Oleszek6, Paul A Romitti7, Christina P Westfield5, Julie Bolen1.   

Abstract

BACKGROUND: For 10 years, the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) conducted surveillance for Duchenne and Becker muscular dystrophy (DBMD). We piloted expanding surveillance to other MDs that vary in severity, onset, and sources of care.
METHODS: Our retrospective surveillance included individuals diagnosed with one of nine eligible MDs before or during the study period (January 2007-December 2011), one or more health encounters, and residence in one of four U.S. sites (Arizona, Colorado, Iowa, or western New York) at any time within the study period. We developed case definitions, surveillance protocols, and software applications for medical record abstraction, clinical review, and data pooling. Potential cases were identified by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 359.0, 359.1, and 359.21 and International Classification of Diseases, Tenth Revision (ICD-10) codes G71.0 and G71.1. Descriptive statistics were compared by MD type. Percentage of MD cases identified by each ICD-9-CM code was calculated.
RESULTS: Of 2,862 cases, 32.9% were myotonic, dystrophy 25.8% DBMD, 9.7% facioscapulohumeral MD, and 9.1% limb-girdle MD. Most cases were male (63.6%), non-Hispanic (59.8%), and White (80.2%). About, half of cases were genetically diagnosed in self (39.1%) or family (6.2%). About, half had a family history of MD (48.9%). The hereditary progressive MD code (359.1) was the most common code for identifying eligible cases. The myotonic code (359.21) identified 83.4% of eligible myotonic dystrophy cases (786/943).
CONCLUSIONS: MD STARnet is the only multisite, population-based active surveillance system available for MD in the United States. Continuing our expanded surveillance will contribute important epidemiologic and health outcome information about several MDs.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Clinical Modification (ICD-9-CM) codes; International Classification of Diseases; MD STARnet; Ninth Revision; active surveillance; medical record abstraction; muscular dystrophies; population-based

Mesh:

Year:  2018        PMID: 30070776      PMCID: PMC6265066          DOI: 10.1002/bdr2.1371

Source DB:  PubMed          Journal:  Birth Defects Res            Impact factor:   2.344


  18 in total

1.  Health services received by individuals with duchenne/becker muscular dystrophy.

Authors:  Shree K Pandya; Kim A Campbell; Jennifer G Andrews; F John Meaney; Emma Ciafaloni
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

2.  Rehabilitative technology use among individuals with Duchenne/Becker muscular dystrophy.

Authors:  Shree Pandya; Jennifer Andrews; Kim Campbell; F John Meaney
Journal:  J Pediatr Rehabil Med       Date:  2016

3.  The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology.

Authors:  Lisa A Miller; Paul A Romitti; Christopher Cunniff; Charlotte Druschel; Katherine D Mathews; F John Meaney; Dennis Matthews; Jiji Kantamneni; Zhen-Fang Feng; Nancy Zemblidge; Timothy M Miller; Jennifer Andrews; Deborah Fox; Emma Ciafaloni; Shree Pandya; April Montgomery; Aileen Kenneson
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-11

4.  Age at onset of first signs or symptoms predicts age at loss of ambulation in Duchenne and Becker Muscular Dystrophy: Data from the MD STARnet.

Authors:  Emma Ciafaloni; Anil Kumar; Ke Liu; Shree Pandya; Christina Westfield; Deborah J Fox; Kristin M Caspers Conway; Christopher Cunniff; Katherine Mathews; Nancy West; Paul A Romitti; Michael P McDermott
Journal:  J Pediatr Rehabil Med       Date:  2016

5.  Neurobehavioral Concerns Among Males with Dystrophinopathy Using Population-Based Surveillance Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network.

Authors:  Kristin Caspers Conway; Katherine D Mathews; Pangaja Paramsothy; Joyce Oleszek; Christina Trout; Ying Zhang; Paul A Romitti
Journal:  J Dev Behav Pediatr       Date:  2015 Jul-Aug       Impact factor: 2.225

6.  Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.

Authors:  Sunkyung Kim; Kimberly A Campbell; Deborah J Fox; Dennis J Matthews; Rodolfo Valdez
Journal:  J Child Neurol       Date:  2014-11-20       Impact factor: 1.987

7.  Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-10-16       Impact factor: 17.586

8.  Respiratory Care Received by Individuals With Duchenne Muscular Dystrophy From 2000 to 2011.

Authors:  Jennifer G Andrews; Aida Soim; Shree Pandya; Christina P Westfield; Emma Ciafaloni; Deborah J Fox; David J Birnkrant; Christopher M Cunniff; Daniel W Sheehan
Journal:  Respir Care       Date:  2016-08-09       Impact factor: 2.258

9.  Patterns of growth in ambulatory males with Duchenne muscular dystrophy.

Authors:  Nancy A West; Michele L Yang; David A Weitzenkamp; Jennifer Andrews; F John Meaney; Joyce Oleszek; Lisa A Miller; Dennis Matthews; Carolyn DiGuiseppi
Journal:  J Pediatr       Date:  2013-10-06       Impact factor: 4.406

10.  Using Administrative Data to Ascertain True Cases of Muscular Dystrophy: Rare Disease Surveillance.

Authors:  Michael G Smith; Julie Royer; Joshua R Mann; Suzanne McDermott
Journal:  JMIR Public Health Surveill       Date:  2017-01-12
View more
  5 in total

1.  High throughput screening for expanded CTG repeats in myotonic dystrophy type 1 using melt curve analysis.

Authors:  Russell J Butterfield; Carina Imburgia; Katie Mayne; Tara Newcomb; Diane M Dunn; Brett Duval; Marcia L Feldkamp; Nicholas E Johnson; Robert B Weiss
Journal:  Mol Genet Genomic Med       Date:  2021-02-24       Impact factor: 2.183

2.  Characterization of individuals with selected muscular dystrophies from the expanded pilot of the Muscular Dystrophy Surveillance, Tracking and Research Network (MD STARnet) in the United States.

Authors:  Bailey Wallace; K Tiffany Smith; Shiny Thomas; Kristin M Conway; Christina Westfield; Jennifer G Andrews; Richard O Weinert; Thuy Quynh N Do; Natalie Street
Journal:  Birth Defects Res       Date:  2020-07-24       Impact factor: 2.661

Review 3.  The ties that bind: functional clusters in limb-girdle muscular dystrophy.

Authors:  Elisabeth R Barton; Christina A Pacak; Whitney L Stoppel; Peter B Kang
Journal:  Skelet Muscle       Date:  2020-07-29       Impact factor: 4.912

4.  Characteristics of Clinical Trial Participants with Duchenne Muscular Dystrophy: Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet).

Authors:  Katherine D Mathews; Kristin M Conway; Amber M Gedlinske; Nicholas Johnson; Natalie Street; Russell J Butterfield; Man Hung; Emma Ciafaloni; Paul A Romitti
Journal:  Children (Basel)       Date:  2021-09-23

5.  A population-based study of mortality due to muscular dystrophies across a 36-year period in Spain.

Authors:  Laura Llamosas-Falcón; Germán Sánchez-Díaz; Elisa Gallego; Ana Villaverde-Hueso; Greta Arias-Merino; Manuel Posada de la Paz; Verónica Alonso-Ferreira
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.